![]() |
市场调查报告书
商品编码
1422065
全球原位杂交市场:按产品类型,技术,探针类型,应用,最终用户,地区,机会,预测2017-2031 年In situ Hybridization Market Assessment, By Product Type, By Technology, By Probe Type, By Application, By End-Users, By Region, Opportunities and Forecast, 2017-2031F |
2023年全球原位杂交市场规模达16.4亿美元。预计到 2031 年,市场规模将达到 35.3 亿美元,2024-2031 年预测期间复合年增长率为 10.04%。全球原位杂交市场充满活力,前景广阔,拥有强大的产品和有利的市场策略。原位杂交市场的推动因素包括癌症患者和遗传疾病盛行率的增加、原位杂交技术在研发中的使用案例的增加以及分子生物学和基因组学的进步。
原位杂交技术在癌症等疾病的诊断和治疗中的有效性已得到证实,并已被医疗保健专业人员广泛采用。近年来,一些研究机构进行了广泛的研究,以探索原位杂交的潜力。它加强了研发场景,并导致对此类产品的需求显着成长。因此,全球癌症患者数量的增加是推动需求的主要因素,因为原位杂交技术在检测癌细胞和基因突变方面非常有效。我是。然而,产品成本高、缺乏熟练的专业人员以及复杂的数据解释是阻碍全球原位杂交市场成长的因素。
该报告研究了全球原位杂交市场,并按产品类型、技术、探针类型、应用、最终用户、地区以及参与市场的公司概况提供了市场概述。更多的。
Global in situ hybridization market size was valued at USD 1.64 billion in 2023 and is expected to reach USD 3.53 billion in 2031, with a CAGR of 10.04% for the forecast period between 2024 and 2031F. The global in situ hybridization market is highly dynamic and promising, with a robust product and favorable market tactics. The in-situ hybridization market is expected to be driven by factors such as the increasing prevalence of cancer cases and genetic disorders, the growing use of in-situ hybridization techniques in research and development, and advancements in molecular biology and genomics.
The proven efficacy of in situ hybridization techniques in diagnosing and managing diseases like cancer led to their growing adoption by healthcare professionals. Several research organizations have spent the last few years conducting extensive research to explore possibilities around in situ hybridization. It has enhanced the research and development scenario and led to significant growth in demand for such products. Hence, growing cancer cases across the globe is a major factor driving the demand for in situ hybridization techniques as it is highly efficient in detecting cancerous cells and genetic mutations. However, the high cost associated with products, lack of highly skilled professionals, and interpretation of complicated data are some hindrances in the growth of the global in situ hybridization market.
In May 2023, Bio-Techne announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) portfolio with the commercialization of RNAscope multi-omic workflow for the Standard BioTools Hyperion Imaging System.
Bio-Techne is an international life sciences firm providing innovative tools and bioactive reagents for research and clinical diagnostics. The RNAscope is considered the gold standard for in situ hybridization and is trusted by biotechnological researchers worldwide, with a rapidly growing list of over 8,000 peer-reviewed publications.
In situ hybridization techniques are used in genetic testing for cancers. These techniques help to detect chromosomal changes in patients and help healthcare professionals to identify the type of cancer, based on which the treatment is designed. Due to vast applications of in situ hybridization, techniques in the diagnosis of cancers and other genetic diseases are further driving the demand in the market. Besides cancers, in situ hybridization techniques are extensively utilized to diagnose other indications like infectious, viral, and immunological diseases. The American Society of Cancer estimates that 1,958,310 new cancer cases and 609,820 cancer deaths in the United States. Cancer Research UK estimates that there will be 28 million cancer cases per year by 2040. It states that the United Kingdom's incidence is ranked higher than 90% of the world.
The global in situ hybridization market is positively impacted by increased research and development surrounding genome exploration, diagnostic research, and its other healthcare and life sciences applications. Over the past few decades, the human genome project has significantly contributed to the growing body of research concerning genetic explorations and life sciences research. The market is anticipated to rise significantly with the growing acceptance and application of in situ hybridization in diagnostic centers, hospitals, and institutional and academic research projects. To increase their worldwide presence, major companies in the market are pursuing tactics including new launches, mergers and acquisitions, and partnerships.
In February 2023, Molecular Instruments (MI), which is a biotech firm under the umbrella of the California Institute of Technology, launched HCR RNA-CISH. The product is expected to stimulate automated chromogenic in situ hybridization (ISH) workflows that depend on Bio-Techne's RNAscope. According to the company, HCR RNA-CISH kits offer twice the turnaround time and half the cost of any current chromogenic in situ hybridization (CISH) method, while delivering superior performance. HCR RNA-CISH has native support for IHC codetection and is fully compatible with all popular automation platforms.
The fluorescent in situ hybridization (FISH) technique finds a vast range of usage in the diagnosis of congenital disorders like Down's syndrome and other genetic diseases including cancer detection and identification. The growing application areas of fluorescent in situ hybridization (FISH) and its growing demand due to the rising burden of cancers and other genetic diseases is expected to make the fluorescent in situ hybridization (FISH) segment dominate the in situ hybridization market. The COVID-19 pandemic significantly boosted in situ hybridization and several research was done on it. For instance, in September 2023, a group of researchers published a protocol in STAR protocol, for the detection of infectious SARS-CoV-2 virus at low levels through in situ hybridization techniques.
North America is anticipated to dominate the market with the highest value share regarding its significant investment in research and development, technical breakthroughs made by major companies, highly developed healthcare infrastructure, and well-established research environment in North American nations like the United States and Canada. The government's actions and initiatives to assist medication development, genetic exploration, and cancer treatment contribute to the market's growth.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of tactics. Companies are expanding the range of products they offer to gain market share. Industry participants are using a variety of growth methods, including collaborations, mergers and acquisitions, partnerships, product launches, and development of new solutions, to bolster their position in the market.
In October 2023, Ikonisys SA partnered with Biocare Medical to expand the FISH diagnostic product portfolio. Biocare Medical is a leading firm providing immunohistochemistry (IHC) and Fluorescent in situ hybridization (FISH) tools and reagents while Ikonisys SA specializes in early and accurate detection of cancer through its unique fully automated solution for medical diagnostic labs. This partnership focuses on expanding the global distribution of products of Ikonisys SA, especially, the low-volume Ikoniscope20 and high-volume Ikoniscope20max. Earlier, Biocare Medical acquired Empire Genomics to expand its offering to include over 1 million FISH probes.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.